Zobrazeno 1 - 10
of 2 766
pro vyhledávání: ''
Publikováno v:
Future Oncology
Introduction: The objective of this study was to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19. Methods: Patients who were tested negative on the Coronavirus disease 2019 (COVID-19) PCR test
Publikováno v:
Anticancer Research. 42:1001-1006
Formation of stoma during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis (PC) is often performed to reduce the risk of anastomotic leak. Subsequent stoma reversal provides a unique oppo
Autor:
Sumiyo Okawa, Takahiro Tabuchi, Kayo Nakata, Toshitaka Morishima, Shihoko Koyama, Satomi Odani, Isao Miyashiro
Publikováno v:
Cancer Science. 113:1047-1056
In Japan, cancer care hospitals designated by the national government have a surgical volume requirement of 400 annually, which is not necessarily defined based on patient outcomes. This study aimed to estimate surgical volume thresholds that ensure
Autor:
Yukihiro, Hama, Etsuko, Tate
Publikováno v:
Anticancer Research. 42:329-334
This study investigated the feasibility and efficacy of multiparametric magnetic resonance imaging (MRI)-guided dose-escalated hypofractionated intensity-modulated radiation therapy with simultaneous integrated boost (IMRT-SIB) for glioblastoma.Eight
Publikováno v:
Bioengineered, Vol 12, Iss 2, Pp 9991-9999 (2021)
Bioengineered
article-version (VoR) Version of Record
Bioengineered
article-version (VoR) Version of Record
Osteosarcoma is known to have a high metastatic potential, which is closely related to angiogenesis. circRNAs are closely associated with osteosarcoma metastasis. This study aims to investigate the role of Circular RNA circFOXP1 in angiogenesis in os
Autor:
Zahra Madjd, Mahdieh Razmi, Sima Saki, Elham Kalantari, Leili Saeednejad Zanjani, Monireh Mohsenzadegan, Fahimeh Fattahi, Maryam Abolhasani
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:609-631
Melanoma-associated antigen A2 (MAGE-A2) is a member of the cancer-testis antigen family differentially overexpressed in a variety of malignancies and is associated with tumor development. However, clinical significance and prognostic value of MAGE-A
Autor:
Muzaffar H. Qazilbash, Mehdi Hamadani, Samantha Jaglowski, Walter Hanel, Madiha Iqbal, Ankit Kansagra, Beth Christian, Ravi Narra, Sairah Ahmed, Mohamed A. Kharfan-Dabaja, Qiuhong Zhao, Krina K. Patel, Narendranath Epperla, Farrukh T. Awan
Publikováno v:
Hematological Oncology. 40:49-57
Waldenstrom macroglobulinemia (WM) is a rare B-cell lymphoproliferative malignancy. Autologous hematopoietic cell transplantation (auto-HCT) is considered in a subset of WM patients with relapsed disease. While registry data has shown a benefit for a
Autor:
Mariko Kobayashi, Satoshi Saitoh, Nozomu Muraishi, Masahiro Kobayashi, Fumitaka Suzuki, Kenji Ikeda, Norio Akuta, Yasuji Arase, Shunichiro Fujiyama, Hiromitsu Kumada, Tetsuya Hosaka, Hitomi Sezaki, Yusuke Kawamura, Yoshiyuki Suzuki
Publikováno v:
Oncology
Introduction: It is unclear whether the relationships between changes in fibrosis and circulating microRNA-122 (miR-122) dynamics might influence the prognosis of nonalcoholic fatty liver disease (NAFLD). Methods: This study investigates the impact o
Autor:
Georgia Karpathiou, Esther Guerra Fernandez, Andres A. Roma, Simona Stolnicu, Graziele Bovolim, Anna Pesci, Robert A. Soslow, Louise De Brot, Esther Oliva, Lien Hoang, Pavel Dundr, Ana Félix, Glauco Baiocchi, Maria José Brito, Antonio Ieni, Kay J. Park, Sofia Lerias, Takako Kyiokawa, Nadeem R. Abu-Rustum, Carlos Parra-Herran, Noorah Almadani
Publikováno v:
J Cancer Res Clin Oncol
PURPOSE: The 2018 International Federation of Gynecology and Obstetrics (FIGO) update on cervical cancer staging eliminated horizontal tumor extent (HZTE) as a staging parameter in stage IA (microscopic) disease. We aimed to determine whether HZTE co
Autor:
Denisa Rozsivalova, Jana Alahakoon, Juraj Kultan, Andrea Mullerova, Kristián Brat, Daniel Krejci, Ondrej Venclicek, Libor Havel, Martin Svaton, Martina Vasakova, Petra Smickova, Ondrej Fischer, Kristyna Hrda, Jana Skrickova, Zsuzsanna Gyorfy, Miloslav Marel, Gabriela Krakorova, P. Opálka, Michal Hrnčiarik, Jaroslav Duba, Jiri Silar, Michal Svoboda, Michal Jirousek, Petr Zuna, J. Krejčí, Lydia Zarnayova
Publikováno v:
Anticancer Research. 41:5549-5556
Background/aim LUCAS is a clinical lung cancer registry (ClinicalTrials.gov identifier is NCT04228237), prospectively collecting data from newly diagnosed lung cancer patients in seven pneumooncology centers in the Czech Republic, since June 1, 2018.